Loading
Norroy Bioscience
Norroy Bioscience is a China-based radiopharmaceutical company that leads 3 cancer trials in OnCo, testing the PSMA-targeted radiopharmaceuticals 177Lu-NYM032 and 68Ga-NYM032 in prostate cancer.
Also called: Norroy Bioscience Co., LTD
Overview
Norroy Bioscience is a clinical-stage company developing therapeutic and diagnostic radiopharmaceuticals together with automated synthesis systems for their manufacture. Its candidates are led by PSMA-targeted 177Lu-NYM032 and 68Ga-NYM032 in prostate cancer and CAIX-targeted tracers in kidney cancer. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo (2 in phase 3 or 2/3): NCT06383052 (phase 1/2, A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC), NCT07615101 (phase 3, Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in...) and NCT07649122 (phase 3, This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imagin...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Wuxi, Jiangsu, CN
Stage
Growth stage
Website
Founded
2021
Connected
4Similar pages
- TechnologyPET (positron emission tomography)
Shares Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer., This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer., Prostate cancer.
cancers
trials
A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPCInvestigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 1
norroybiopharm.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/